In a postmenopausal woman with hypoactive sexual desire, how does the testosterone transdermal patch (Testavan) compare to a 2% testosterone gel regarding dosing, efficacy, and safety?

Testavan vs Testosterone 2% Gel for Postmenopausal Women with HSDD

For postmenopausal women with hypoactive sexual desire disorder, use a transdermal testosterone patch (300 µg/day) rather than testosterone gels, as patches have the strongest evidence for efficacy and safety in this specific population.

Key Recommendation Based on Evidence

The most robust data support testosterone transdermal patches at 300 µg/day for treating HSDD in postmenopausal women 1, 2. While Testavan (2% testosterone gel) is a newer formulation 3, the evidence hierarchy clearly favors patches:

Efficacy Data

Testosterone patches (300 µg/day) demonstrate:

• Increase of 1-2 additional satisfying sexual events per month compared to placebo 2
• 73-115% improvement in satisfying sexual activity 2
• Significant improvements across all sexual function domains: desire, arousal, orgasm, pleasure, responsiveness 1, 2
• 65-68% reduction in personal distress vs 40-48% with placebo 2
• Benefits demonstrated in both surgically and naturally menopausal women, with or without concurrent estrogen therapy 2, 4

Testosterone gels (including 2% formulations) have contradictory evidence:

• Two large Phase III trials of transdermal testosterone gel (0.22 g/day) showed no benefit over placebo for satisfying sexual events or sexual desire 2
• The 2% gel formulation (Testavan) lacks specific efficacy data in women with HSDD 3

Dosing Considerations

Patches:

• Standard dose: 300 µg/day applied twice weekly
• Doses of 150 µg/day showed inconsistent benefit 2
• Doses of 450 µg/day caused supraphysiological testosterone levels 2

2% Testosterone Gel:

• FDA-approved formulations are designed for men only 5
• Male gel formulations (1.62%) require application to upper arms/shoulders with doses of 20.25-81 mg daily 5
• No approved female-specific dosing exists for 2% gels in the US 1, 6

Safety Profile

Critical safety concern with gels: Risk of secondary exposure to children and women through skin-to-skin contact 5. FDA labeling emphasizes:

• Children exposed to testosterone gel have developed virilization (genital enlargement, pubic hair, advanced bone age) 5
• Transfer risk increases significantly without proper precautions
• Requires covering application site with clothing, handwashing, and avoiding contact for 2+ hours 5

Patches demonstrate:

• Androgenic side effects (primarily unwanted hair growth) in 30% vs 23% placebo 7
• No serious adverse events in short-term studies 8, 6
• Testosterone levels remain within physiological premenopausal range 2, 4

Clinical Algorithm

Step 1: Confirm diagnosis of HSDD through clinical assessment (not testosterone levels) 1, 6

• Low desire causing personal distress
• Not primarily due to relationship problems, mental health issues, or modifiable factors 6

Step 2: Obtain baseline total testosterone level (for monitoring, not diagnosis) 1, 6

Step 3: Prescribe testosterone patch 300 µg/day, applied twice weekly 1, 2, 6

Step 4: Monitor at 3-6 months:

• Assess clinical response (satisfying sexual events, desire, distress)
• Check testosterone levels to ensure physiological premenopausal range
• Evaluate for androgenic side effects 6

Important Caveats

1. No FDA-approved testosterone formulation exists for women in the US 1, 9, 6, 10
2. All use is off-label and requires informed consent discussion 6
3. Compounded preparations cannot be recommended due to lack of efficacy and safety data 1, 6
4. Long-term safety data (>52 weeks) are insufficient, particularly regarding cardiovascular and breast cancer risk 7, 9, 10
5. Avoid injectables, pellets, or supraphysiological dosing 1, 10

Why Not 2% Gel?

The 2% testosterone gel (Testavan) has three critical limitations:

• No efficacy data in women with HSDD 3
• Designed and tested only in hypogonadal men 3
• Higher secondary exposure risk compared to patches, particularly dangerous for children 5

The global consensus position statement explicitly recommends against formulations lacking women-specific data 1, and the Endocrine Society guidelines emphasize that only transdermal patches have Level I, Grade A evidence for HSDD treatment 2.